International Journal of Epilepsy 2016; 03(01): 42-62
DOI: 10.1016/j.ijep.2015.12.040
Thieme Medical and Scientific Publishers Private Ltd. 2017

Demographics of epilepsy and antiepileptic drugs utilization in India: Results of an observational study

Sanket Newale
1   Neurologist, Pune
› Author Affiliations

Subject Editor:
Further Information

Publication History

Publication Date:
12 May 2018 (online)

Objective: To understand demographic profile and treatment modalities and co-morbidities in patients with epilepsy.

Material and methods: A cross-sectional, observational, non-interventional study was conducted among adult Indian patients with epilepsy. Demographic information, epilepsy type, seizure control, seizure freedom with current therapy, comorbid conditions and usage pattern of antiepileptic agents (AED) according to age group and gender were recorded. Safety was assessed by recording adverse drug reactions.

Results: The study included 973 patients (females 38.7%) with mean age of 35.6 years. Only 3.56% patients were not educated while 45.31% patients were employed. Only 1.2% patients had history of brain injury. The mean frequency of seizures during previous six months was 24.0 (±49.12) while the mean duration of epilepsy was 5.8 (±5.78) years. EEG was the most common (59.7%) investigation modality. A total of 109 (11.2%) patients had comorbid medical illness among which hypertension was seen in 29.36% patients. Levetiracetam was used in 583 (59.9%) patients while valproate, clobazam, and phenytoin were used in 16.3%, 14.8% and 13.6% patients respectively. Effectiveness and safety/tolerability profile were two most important considerations for selecting AED. A total of 924 (95.00%) had seizure control with during previous six months while mean seizure free interval was 7.1 (±4.09) months. Levetiracetam was used in 34.92%. 45.73% and 61.11% patients and valproate in 15.16%, 10.85% and 4.55% patients in the age group of 18–30, 31–50 and 51–75 years respectively. Levetiracetam was used in 57.72% and 63.40% while valproate was used in 18.96% and 11.67% male and female patients respectively. Adverse event rate was only 0.1%.

Conclusion: Epilepsy is common in adult patients. Hyper-tension is the most common comorbidity. Levetiracetam is the most commonly used AED across all studied age groups and in both genders. Control of epilepsy with current treatment is satisfactory with no major adverse events.